Eli Lilly and Company

LARTRUVO

Manufacturer:

Eli Lilly and Company

Lartruvo HCPCS:

J9285

HCPCS Code Descriptor:

Injection, olaratumab, 10 mg

Category:

J Code

Lartruvo NDCs:

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Lartruvo:

LARTRUVO is an Oncology drug manufactured by Eli Lilly and Company and administered via the Intravenous route of administration. The J Code: J9285 is aligned to the drug LARTRUVO.

ACCESS PRICING AND MORE BY REGISTERING

J9285 Added Date:

January 1, 2018

J9285 Effective Date:

January 1, 2023

J9285 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Lartruvo billing and coding information.
Lartruvo patient assistance information can be found through Lilly Support Center at the URL: https://www.lillyoncologysupport.com/hcp
LARTRUVO prescribing information can be found at the link below:
Information regarding LARTRUVO’s side effects can be found at MedlinePlus